Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Loncastuximab Tesirine in Specific Populations of Relapsed/Refractory B-Cell Malignancies

NCT05453396 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT05453396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05453396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Loncastuximab Tesirine in Specific Populations of Relapsed/Refractory B-Cell Malignancies
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Terminated
Start date
August 7, 2023
Completion date
May 21, 2026
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent b-cell non-hodgkin lymphoma, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent mantle cell lymphoma, refractory b-cell non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma, refractory mantle cell lymphoma